Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 12/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766368 | 0.88 | RBP4 (0.63) | RBP4SIGMAR1DRD2GFER | |
| SCHEMBL7983470 | 0.87 | SIGMAR1 (0.59) | RBP4SIGMAR1DRD2GFERKMT2A | |
| SCHEMBL631705 | 0.86 | RBP4 (0.70) | RBP4GFERKMT2ARAB9A | |
| SCHEMBL633153 | 0.86 | RBP4 (0.74) | RBP4GFERKMT2ARAB9A | |
| SCHEMBL766389 | 0.86 | SIGMAR1 (0.62) | RBP4SIGMAR1DRD2KMT2AMEN1 | |
| SCHEMBL13039955 | 0.84 | SIGMAR1 (0.59) | RBP4SIGMAR1DRD2KMT2ARAB9A | |
| SCHEMBL766312 | 0.83 | KMT2A (0.70) | RBP4GFERKMT2ARAB9A | |
| SCHEMBL7971897 | 0.83 | SIGMAR1 (0.55) | RBP4SIGMAR1DRD2GFERKMT2A | |
| SCHEMBL27495677 | 0.83 | SIGMAR1 (0.55) | RBP4SIGMAR1DRD2GFERKMT2A | |
| SCHEMBL767033 | 0.81 | RBP4 (0.60) | RBP4DRD2KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RBP4 1/4885SIGMAR1 4495/4885DRD2 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.